Risk and characteristics of interstitial lung disease in patients with inflammatory bowel disease: A retrospective cohort study.
Sarcoidosis vasculitis and diffuse lung diseases · 30.09.2026 · 43 (3) · 18654-18654
DOI: 10.36141/svdld.2026.18654 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 30.09.2026. Verfasst von Amarilys Alarcon-Calderon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Inflammatory bowel disease (IBD) is a disorder with extraintestinal manifestations that may involve multiple organ systems. Interstitial lung disease (ILD) is an extraintestinal manifestation that remains underrecognized, and its prevalence, clinical characteristics, and risk factors in IBD are poorly defined. METHODS: We conducted a retrospective study of adults (≥18 years) with IBD who had at least 1 clinical encounter at our hospital between January 1, 2013, and December 31, 2023. IBD and ILD diagnoses were identified by using International Classification of Diseases, Ninth [or Tenth] Revision, Clinical Modification codes, and ILD diagnoses were confirmed by a thoracic radiologist. Demographic and clinical characteristics were abstracted from the electronic health record. Associations between patient characteristics and ILD were evaluated with 2 analyses: cross-sectional cohort and matched case-control. Risk of death was assessed by using a Cox proportional hazards model with ILD as a time-dependent covariate. RESULTS: Among 875 patients with IBD, 109 (12%) had ILD. Radiographic patterns of ILD most commonly showed nonspecific interstitial pneumonia (27%), indeterminate (26%), and usual interstitial pneumonia (24%). Pulmonary function testing most commonly showed restriction (59%) and impaired diffusing capacity (61%). The cohort analysis showed that higher BMI, bronchiectasis, history of smoking, and use of adalimumab or infliximab were independently associated with ILD. The case-control analysis confirmed these findings and identified older age as another significant factor. ILD was associated with a higher risk of death (hazard ratio, 3.78; 95% CI, 2.50-5.72; P
Schlagwörter
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
- Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA, Department of Internal Medicine, North Mississippi Medical Center, Tupelo, MS, USA.
- Department of Radiology, Mayo Clinic, Rochester, MN, USA.
- Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Amarilys Alarcon-Calderon
Zitieren
APA
Alarcon-Calderon, A., Pranav, M., Wireko, F., Abdulla, S., Kruger, L. F., Liu, E., Schulte, P. J., Ryu, J. H., & Baqir, M. (2026). Risk and characteristics of interstitial lung disease in patients with inflammatory bowel disease: A retrospective cohort study. Sarcoidosis vasculitis and diffuse lung diseases, 43(3), 18654-18654. https://doi.org/10.36141/svdld.2026.18654
Vancouver
Alarcon-Calderon A, Pranav M, Wireko F, Abdulla S, Kruger LF, Liu E, et al. Risk and characteristics of interstitial lung disease in patients with inflammatory bowel disease: A retrospective cohort study. Sarcoidosis vasculitis and diffuse lung diseases. 2026;43(3):18654-18654. doi:10.36141/svdld.2026.18654
BibTeX
@article{AlarconCalderon2026,
author = {Alarcon-Calderon, Amarilys and Pranav, Modi and Wireko, Felix and Abdulla, Salma and Kruger, Livia F and Liu, Emily and Schulte, Phillip J and Ryu, Jay H and Baqir, Misbah},
title = {Risk and characteristics of interstitial lung disease in patients with inflammatory bowel disease: A retrospective cohort study},
journal = {Sarcoidosis vasculitis and diffuse lung diseases},
year = {2026},
volume = {43},
number = {3},
pages = {18654--18654},
doi = {10.36141/svdld.2026.18654}
}
EUVIMED